Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Equity Average (2016 - 2025)

ImmunityBio (IBRX) has disclosed Equity Average for 11 consecutive years, with -$511.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 16.98% to -$511.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$511.9 million, a 16.98% increase, with the full-year FY2025 number at -$494.8 million, up 7.95% from a year prior.
  • Equity Average was -$511.9 million for Q4 2025 at ImmunityBio, up from -$546.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$151.9 million in Q1 2021 to a low of -$720.8 million in Q3 2024.
  • A 5-year average of -$460.2 million and a median of -$505.1 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: crashed 6850.95% in 2021, then increased 24.16% in 2025.
  • ImmunityBio's Equity Average stood at -$216.9 million in 2021, then plummeted by 102.58% to -$439.5 million in 2022, then fell by 13.39% to -$498.3 million in 2023, then fell by 23.75% to -$616.6 million in 2024, then increased by 16.98% to -$511.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Equity Average are -$511.9 million (Q4 2025), -$546.6 million (Q3 2025), and -$580.2 million (Q2 2025).